Specialist · Montreal, QC
Sectoral Asset Management
Healthcare investing, public and private.
- Cheque
- $6M to $20.4M
- Role
- Can lead a round
- Pace
- Selective right now
- Kind
- Specialist
- Based in
- Montreal, QC
- Vehicle size
- $136M
- Founded
- 2000
- Works in
- EN + FR
- Last deal seen
- April 2026
- Stages
- Seed, Series A, Series B and later
- Sectors
- Health and biotech
Their thesis, in full
Montreal healthcare specialist founded in 2000, running both public equity and venture capital strategies. The venture activity has invested since 2008 through the New Emerging Medical Opportunities (NEMO) funds, which back clinical stage biotech and medtech companies across North America and Europe, typically at Series B or later, and lead or co-lead most initial investments with a board seat. NEMO VI held its first close on February 2, 2026 at USD 100 million, with an objective of USD 200 million by the end of 2026. In 2023 Sectoral launched the Fonds Medtech Ventures, an early-stage fund for Canadian medtech companies at Series A or first institutional round, whose first close reached CAD 41.5 million with Investissement Quebec and the Fonds de solidarite FTQ.
What they bring past the cheque
- Life sciences depth
- Public-private bridge
- Medtech expertise
- Transatlantic network
- Clinical diligence
Questions they usually ask
Have an answer ready for each one before the first call.
- What clinical or regulatory milestones unlock the next valuation step?
- How does your differentiated technology compare to incumbents in North America and Europe?
- What is your reimbursement and payer strategy at commercial launch?
Follow-on
Sectoral reserves capital for follow-on rounds through clinical and regulatory milestones, and has re-invested as an existing investor in Iantrek, Neuros Medical, Cagent Vascular and Apnimed. It syndicates with specialist healthcare investors including OrbiMed, Northpond Ventures, Cormorant Asset Management and Deerfield. Founders share milestone-driven updates and a clear regulatory and reimbursement roadmap.
Who to talk to
- Marc-Andre MarcottePartner & Head of Venture Capital
- Michael SjostromCo-Founder & Partner
- Francois BeaubienPartner
- Stefan LarsonVenture Partner
- Gabriel DouvillePrincipal
- Howard RibackDirector, Venture Capital
- Christopher KentPrincipal
- Kevin VosAssociate
Portfolio
Names they back, most notable first.
- Route 92 MedicalSeries B+ · 2026
- Antegrade MedicalSeed · 2025
- Leaflet SolutionsSeed · 2025
- SecondWave SystemsSeries A · 2025
- IantrekSeries B+ · 2025
- Neuros MedicalSeries B+ · 2025
- Cagent VascularSeries B+ · 2024
- PhagenesisSeries B+ · 2024
- CurvaFixSeries B+ · 2023
- Miach OrthopaedicsSeries B+ · 2023
- ApnimedSeries B+ · 2023
- Magnolia Medical TechnologiesSeries B+ · 2022
Often in the same rounds
Investors seen alongside them in past rounds.
- Cormorant Asset Management
- Northpond Ventures
- OrbiMed
- Deerfield Management
Similar investors
Overlapping sectors and stages. Useful to build a list of 10 to 20 names for one round.
See how they fit your round
Set your stage, sector and amount once. Fractal App tells you if Sectoral Asset Management can lead it, tracks every follow-up, and counts the days of silence. Free, no card.
Open in the app →